We use cookies to provide you with a better experience. By continuing to browse the site you are agreeing to our use of cookies in accordance with our Cookie Policy.
Sandoz has agreed to pay $195 million to settle charges related to the Department of Justice’s three-year antitrust investigation into the generic drug industry, the company announced yesterday. Read More
The latest decision ends the drugmakers’ Truvada patent challenges before the board. The matter is now in the hands of the U.S. District Court for the District of Delaware, where HHS has sued the drugmaker for patent infringement. Read More
Opioid makers and 37 Attorneys General told an Ohio federal court that proposed attorney fees could derail a global settlement in the opioid multidistrict litigation. Read More
The FDA unveiled a pilot program last week that will use plain language and podcasts to explain its guidance documents in snapshots posted to its website. Read More
The Council of Economic Advisers estimated that revenues for non-U.S. drugmakers would have been $194 billion higher in 2017 if foreign drug prices reflected the countries’ Gross Domestic Product. Read More
A Kansas federal judge has certified two classes in an antitrust suit against Pfizer and Mylan over an alleged scheme to raise the price of EpiPen (epinephrine injection USP). Read More
The FDA should seek authority from Congress to require drug companies to disclose the “complete physical path” of products through the supply chain, HHS Office of Inspector General (OIG) recommended in a new report. Read More